Overview

Efficacy and Safety of Silfamin for Common Cold

Status:
COMPLETED

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This is a 2-arm, prospective, randomized, double-blind, placebo-controlled, and three-days-treatment clinical study comparing the efficacy and safety of Silfamin at a dose of 2 tablets@150 mg twice daily in subjects with common cold.

Phase:

PHASE2

Details

Lead Sponsor:

Dexa Medica Group

Collaborator:

Fakultas Kedokteran Universitas Indonesia